Cannabis Triumphs: Aurora Cannabis Reports Q1 2024 Surge in Sales and International Success
In a remarkable turn of events, Canadian licensed producer Aurora Cannabis has unveiled its Q1 2024 financial report, showcasing a remarkable surge in plant-propagation sales and medical marijuana exports. This achievement has led to a substantial reduction in the company’s losses, narrowing down to 28.3 million Canadian dollars ($20 million) – a striking improvement compared to the staggering CA$618.8 million loss reported in the same quarter last year.
Notably, the company’s success can be attributed to its flourishing international ventures and strategic shifts. Aurora’s prudent decision to wind down its American CBD business, Reliva, has been informed by the potential CBD-regulation pathways and timeline announcements from the U.S. Food and Drug Administration. Despite this change, Aurora remains on a trajectory of positive growth, reporting adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of CA$2.2 million for the quarter ending June 30, 2023. This marks a stark contrast to last year’s quarter, which saw a loss of CA$8.8 million.
The fiscal year 2023, consisting of only three quarters, has also witnessed the company’s adept management of assets and expenses. A significant decrease of CA$457.5 million in impairment of intangible assets and goodwill, coupled with a CA$78.7 million reduction in property, plant, and equipment impairment, contributed to the company’s improved financial standing. Lower operating expenses further added to this positive trend.
In an exclusive interview with MJBizDaily, Aurora CEO Miguel Martin acknowledged the tough decisions made in the quarter, including the closure of Reliva. Martin, previously at the helm of Massachusetts-based Reliva, brought his insightful leadership to Aurora.
Alongside this, Aurora is also discontinuing its partnership with Dutch cannabis producer Growery – a deal that had garnered attention upon its announcement in 2021. Martin emphasized the company’s commitment to markets with a predictable regulatory framework, even if progress is gradual. The Dutch market, once promising for both medical and recreational opportunities, underwent significant shifts that led Aurora to reevaluate its investment. Martin stated, “The recreational opportunity went from 500 coffee shops throughout the country and legalizing the wholesale business, which would have made a lot of sense, to not really being an opportunity at all. It just didn’t make any sense to stay with it.”
The upward trajectory in Aurora’s performance is further evidenced by its substantial increase in net revenue for the quarter – a striking 50% year-over-year surge to CA$75.1 million. This robust growth can be attributed to strong exports, particularly in the international medical cannabis sector, which saw revenue surge by 40% to CA$16.2 million.
Remarkably, Aurora’s agricultural propagation unit has significantly contributed to this success. Net revenue from plant propagation reached CA$19.9 million, marking a historic high for the Bevo Agtech subsidiary. This achievement can be attributed to the company’s strategic acquisition of Bevo in August 2022. The seasonality of Bevo’s business model, with a substantial portion of revenue generated in the first half of the calendar year, further bolsters these results.
Aurora’s comprehensive medical cannabis net revenue, encompassing both Canada and overseas, witnessed a commendable 14% increase from the previous year, amounting to CA$41.2 million for the quarter. Notably, Canadian medical cannabis net revenue for the April-June quarter reached CA$25.4 million, slightly surpassing last year’s figures. This growth is attributed, in part, to increased sales to insured patient groups. The adult-use market also experienced a slight increase in revenue, rising from CA$12.6 million to CA$13.2 million.
The convergence of cost-saving strategies and revenue growth has propelled Aurora towards a promising future. The company’s projections indicate a trajectory toward achieving positive free cash flow by the calendar year 2024, marking a significant milestone in its journey of consistent success.
